ImmunityBio Inc. stocks have been trading up by 7.87 percent following upbeat sentiment around its latest cancer therapy progress.
Click Here for a Millionaire's POV on Trading IBRX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Shares are up 12.4%, or $1.15, with ImmunityBio recently trading near $10.43 after a string of strong sessions
- The stock earlier jumped 11.6% to $10.36 in fast, news‑driven trading that lit up momentum screens
- Management will present at a Piper Sandler Virtual Oncology Symposium, with Dr. Patrick Soon‑Shiong updating traders on ANKTIVA and the immunotherapy pipeline
- Soon‑Shiong is also leading a PIPE into PDS Biotechnology and joining PDSB’s board, building out his oncology ecosystem
- A recent Form 4 shows a change in beneficial ownership of IBRX, though the direction and size remain undisclosed
Live Update At 12:32:07 EDT: On Friday, October 09, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 7.87%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
ImmunityBio Inc. has turned into a momentum playground. IBRX climbed from late‑September closes around the mid‑$8s to over $10 in early October, with recent action pushing as high as $10.69. That is a big percentage move in a short window, and traders need to remember the fundamentals underneath are still highly speculative.
On the numbers, IBRX is classic clinical‑stage biotech: meaningful revenue, but very heavy losses. The company logged about $51.2M in quarterly revenue, yet reported a net loss of roughly $230.4M and an EBITDA loss near $194.7M. Profit margins are deeply negative, and return on assets is sharply below zero. That tells traders the current valuation is almost entirely about future potential, not current earnings power.
More Breaking News
- DNN Stock Drifts Lower As Uranium Trader Focus Tightens
- NOK Stock Slides As European ADR Weakness Deepens
- SAIQ Stock Rockets After Nasdaq Debut And Funding Deal
- XRTX Stock Jumps As Gout Drug Program Accelerates
At the same time, ImmunityBio’s balance sheet shows some breathing room. Cash, cash equivalents, and short‑term investments total about $357.4M, with a strong current ratio around 5.7. Free cash flow is still firmly negative at about -$70.0M for the quarter, so dilution and financing risk remain on the table. For short‑term traders in IBRX, this is a story of volatility and catalysts, not steady cash generation.
Why Traders Are Watching IBRX Momentum
Over the past few sessions, IBRX has done exactly what short‑term traders look for: stack one high‑volume move on top of another. ImmunityBio shares first spiked 11.6% to $10.36 in early trading, then extended the move to a 12.4% gain, changing hands near $10.43. When a biotech like ImmunityBio strings those gains together, algorithms and day traders pile in, turning a quiet chart into a momentum battlefield.
The daily candles back that story up. IBRX has pushed from a close of $8.37 on 2026/09/14 to levels above $10 by 2026/10/09. Recent intraday action shows tight stair‑stepping from about $9.95 at the open to highs around $10.69, with shallow pullbacks and steady higher lows. That is the kind of intraday trend momentum traders love: clear direction, defined dips, and plenty of liquidity.
What is lighting this fire? A big part of the narrative is visibility. ImmunityBio will appear at a Piper Sandler Virtual Oncology Symposium, where founder and executive chairman Dr. Patrick Soon‑Shiong is set to talk about ANKTIVA and the broader ImmunityBio pipeline. Events like this often reset expectations. Traders in IBRX know that even without fresh trial data, a confident tone or new color on strategy can fuel speculative buying.
Around the edges, Soon‑Shiong’s PIPE financing into PDS Biotechnology and his new board role at PDSB give the ImmunityBio story an ecosystem angle. It suggests he is knitting together a broader oncology platform, which some traders read as long‑term conviction in immunotherapy. Meanwhile, a recent Form 4 filing flagged a change in IBRX beneficial ownership, but with no detail on direction or size, it serves more as background noise than a clear trading trigger.
Conclusion
ImmunityBio Inc. is acting like a textbook high‑beta biotech runner. IBRX has surged from the high‑$7s and low‑$8s in mid‑September to trade above $10 in October, with back‑to‑back double‑digit percentage pops. Underneath that chart, the fundamentals are still early‑stage: steep quarterly losses around $230.4M, negative returns, and a price that leans heavily on future success for ANKTIVA and the wider ImmunityBio pipeline. This is not a cash‑cow story; it is a speculation on science and execution.
For active traders, the key near‑term catalyst is the upcoming Piper Sandler oncology symposium appearance. Any new color from Dr. Patrick Soon‑Shiong on ANKTIVA, trial timelines, or regulatory plans could jolt IBRX in either direction. His parallel move into PDS Biotechnology, and his growing oncology network, add another narrative layer that momentum traders can latch onto, even if the direct financial impact on ImmunityBio is limited right now.
The tape tells you this stock can move fast. That demands a clear trading plan. As Tim Sykes likes to remind his community, “The pattern is only part of the puzzle — the real edge comes from preparation, discipline, and cutting losses quickly when the trade proves you wrong.” That mindset lines up closely with another core trading principle: As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.”. For anyone studying IBRX, the lesson is simple: respect the volatility, know the catalysts, and never confuse a hot chart with guaranteed success. This analysis is for educational and research purposes only, not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.